BioMarin Pharmaceutical Inc. reports results for the quarter ended June 30 - Earnings Summary

BioMarin Pharmaceutical

06/08/2026 22:37

BioMarin Pharmaceutical Inc. BMRN.OQ reported quarterly adjusted earnings of 73 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $1.23.  The mean expectation of twenty three analysts for the quarter was for earnings of 69 cents per share. Wall Street expected results to range from 35 cents to 95 cents per share.
Revenue rose 19.9% to $989.71 million from a year ago; analysts expected $926.91 million. 
BioMarin Pharmaceutical Inc.'s reported EPS for the quarter was 23 cents​.
The company reported quarterly net income of $44.76 million.
BioMarin Pharmaceutical Inc. shares had risen by 4.7% this quarter and gained 0.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 16% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc. is $87.83, about 31.8% above its last closing price of $59.91
This summary was machine generated from LSEG data August 6 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.69
0.73
Beat
Mar. 31 2026 
0.75
0.54
Missed
Dec. 31 2025 
0.62
-0.24
Missed
Sep. 30 2025 
0.37
-0.16
Missed